Smith & Nephew swoops for US medicine firm in £500m deal
Smith & Nephew, the Hull-headquartered medical technology firm, has agreed to acquire a US-based regenerative medicine business in a deal worth more than £500m.
Osiris Therapeutics delivers regenerative medicine products, including skin, bone graft and articular cartilage substitutes.
The Nasdaq-listed firm delivered revenues of $102m for the nine months ending 30 September 2018, an 18.7% increase over the same period in 2017.
Smith & Nephew have valued Osiris’ shares at $19 each, representing a total equity value... For the full story register now for free or login below...